ABOUT THE COMPANY
Manhattan-based TMRW is a mission-driven company on track to become the first mover in automating the IVF lab by creating the first fertility cryostorage center of excellence in the world. TMRW features fully robotic freezers, 100 percent physical and digital chain of custody, continuous monitoring of egg and embryo samples and electronically integrated processes—all overseen at the TMRW control center. The firm is structured in anticipation of an IPO with leading assisted reproductive technology (ART) physicians as customers, clinical partners and significant equity holders.
TMRW is seeking a high-energy, entrepreneurial-minded Digital Director to work closely with the CMO and executive team in the development and implementation of dynamic marketing strategies related to business-to-business-to-consumer marketing. The Digital Director is responsible for bringing to life the brand storytelling and activations within the company's digital ecosystem which sometimes will include third- party partner's digital channels as well. The role is integral in the continued development of the TMRW brand both domestically and in the near future European expansion.
KEY DUTIES AND RESPONSIBILITIES:
ABOUT ASSISTED REPRODUCTIVE TECHNOLOGY (ART)
It's becoming increasingly apparent that fertility medicine represents one of the triumphs of the last 50-years of medical history. Today, one in 20 children born in Japan is the result of ART. In Norway, the number is one in 10. Powerful, irreversible scientific and demographic forces are driving this development. Today the advantages of involving a fertility doctor in the process of conceiving a child are numerous—and growing rapidly. For women, it allows them to better safeguard their fertility over a longer period of time. For all would-be parents, a growing list of devastating, often fatal genetic conditions (Tay Sachs, Sickle Cell Anemia, Cystic Fibrosis) can be screened against and easily avoided, affording the opportunity to end certain disease states within a generation. All of these advances are linked to the newly perfected technology of vitrification - the fast freezing of human embryos and oocytes (eggs). As the advantages of vitrification mount, ART is quickly becoming a "freeze all" clinical practice requiring both long-term and short-term cryostorage in the next decade for millions of patients, up from only 5,000 just a few years ago. The existing cryostorage infrastructure in medical clinics can no longer accommodate this growing demand.
ABOUT THE FOUNDERS
TMRW's three co-founders—Joshua Abram, Alan Murray and Jeff Port--- are serial entrepreneurs who have founded and led firms involved in diverse fields including data and analytics, biomedicine and hospitality.
Prior to founding TMRW, Joshua and Alan—operating through Coriolis Ventures— founded and served as Co-CEOs of several venture-backed companies at the intersection of data, machine learning and marketing. These companies today employ approximately 1,000 people, mostly in Manhattan, and routinely process tens of billions of data events every 24 hours. While building these technology companies, Joshua and Alan also made a significant commitment to founding and/or providing the earliest seed funding to firms that spoke to their shared interest in hospitality and innovative commercial and saleable luxury experiences. They co-founded the paradigm-shifting NeueHouse, which brought the amenities and sensibility of a boutique hotel to the office environment and was widely celebrated for, as Departure Magazine wrote, fundamentally changing "what one might aspire to in a utopian, perfected office." Joshua and Alan also provided the earliest seed funding to Alice, a hospitality technology company automating the guest experience at leading hotels which later received $30 million in funding from Expedia.
Jeff Port is a thoracic surgeon who, while practicing and teaching full-time at Weill Cornell Medical Center, founded RF Surgical which developed a now widely used technology to track items used by surgeons during complex operations to assure that nothing is left behind after wound closure. Companies founded by the TMRW principals have enjoyed exits totaling over $1 billion.
Job Type: Full-time